Three-year follow-up trial data successfully demonstrates survival benefit of Oncimmune’s Early-CDT lung cancer diagnostic

Oncimmune Holdings plc (LON:ONC) drew attention to the pre-publication of new research demonstrating how the use of its EarlyCDT-Lung Test, for diagnosing early stage lung cancer, has been shown to reduce mortality when used as part of a cancer screening protocol. The study is based on three-year follow up data from the Early detection of Cancer of the Lung Scotland (“ECLS”) trial. The study validates the commercial value of Early-CDT, which is currently being supplied to the UK NHS, and marketed in the US by Biodesix (with fees payable to Oncimmune). The results will support the continuing sales growth, and accompanying earnings contribution, of the blood based diagnostic test. Our valuation and current forecasts are currently under review pending an update by a new analyst. 

Pre-publication of research paper posted on the medRXiv server

The paper entitled Targeted screening for lung cancer with autoantibodies, will in due course be officially published. The research is based upon a study of 12,208 smokers and ex-smokers, recruited from General Practices in Scotland, aged 50-75 and at risk of developing lung cancer. Patients were tested for lung cancer using EarlyCDT, and if positive subjected to low-does CT scanning every 6-months for up to two years. Patients tested negative using EarlyCDT received standard of care. The study reported results of a three year follow-up.

Patients tested positive using EarlyCDT showed significant survival benefit

After three years, the number of late-stage lung cancer deaths were significantly lower in patients tested with the EarlyCDT Lung blood test. Observable, but non-significant reductions in all cause and lung cancer deaths were also noted.

As perhaps expected, EarlyCDT detected early stage cases of lung cancer in patients initially screened, and did not enable diagnosis as cancers developed later in the follow-up period. The investigators noted that screening programmes of ‘at risk’ individuals should repeat the Early-CDT® test at regular intervals (i.e. multiple tests per patient) to detect newly arising cancers.

Positive research results will likely support ongoing demand for EarlyCDT

Oncimmune’s June 2021 trading statement noted that over Q4 FY2021 additional NHS commercial supply contracts were signed with the NHS for EarlyCDT, with additional NHS supply contacts expected. In addition, sales of the test by US marketing partner Biodesix witnessed a strong recovery in demand, after a COVID-based lull. The recovery in US sales, and increasing use of the test by the UK NHS, is expected to continue throughout FY2022.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Fintel plc

    Fintel Plc appoint Phil Smith as Non-Executive Director

    Fintel plc (LON: FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has announced the appointment of Phil Smith as Independent Non-Executive Director with immediate effect. Following a robust process led

    Pendragon plc

    Pendragon underlying Profit before Tax of £18.7m, up 73.1%

    Pendragon plc (LON:PDG) has announced its interim management statement. This Interim Management Statement covers the period from 1 January 2022 to 31 March 2022.  Unless otherwise stated, figures quoted in this statement are for the three

    SpaceandPeople returns to profit

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued full

    SpaceandPeople back into profit and positive earnings per share

    SpaceandPeople plc (LON:SAL) the retail, promotional and brand experience specialist, has announced its final results for the year ended 31 December 2021.   Financial Highlights ·       Revenue of £4.0 million (2020: £2.8 million and 2019: £7.7 million) ·       Operating profit of

    tinyBuild plc

    tinyBuild acquihires development studio Demagic Games

    tinyBuild plc (LON:TBLD), a premium video games publisher and developer with global operations, has announced the acquihire of Demagic Games, a development studio with 23 staff[1] currently based in Ukraine and Russia. The Company has been working

    Vertu Motors Plc

    Vertu Motors share buyback programme update

    Vertu Motors plc (LON: VTU) has announced that on 07 April 2022, it purchased 201,999 ordinary shares of 10p each in the Company on the London Stock Exchange, pursuant to the share buyback programme that was announced on 2nd March 2022 as

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Lookers Plc

    Lookers shares to trade in excess of 150p says Zeus

    Lookers plc (LON:LOOK) has announced FY21 results that show record underlying PBT of £90.7m, 5.3% above our forecast of £86.2m. The outlook is suitably cautious given current supply constraints and likely impact of inflation on future